NCT01382589View on ClinicalTrials.gov

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

December 31, 2012

Conditions
Vitiligo
Interventions
DRUG

Afamelanotide

NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation

DEVICE

NB-UVB

NB-UVB light therapy 3-times per week, for total of 72 treatments

Sponsors
All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY